Campbell Lockhart

CAMPBELL LOCKHART

Campbell Lockhart is presently helping innovation practitioners write innovation scenarios that are applied to transforming ideas into value. He has been an innovation practitioner for over 30 years, working as a medical technology developer, an open innovation manager in a FMCG giant, an open innovation service provider and as an open innovation solution provider. He currently manages an open innovation platform that aggregates innovation needs into a one-stop-shop where solution providers can rapidly identify industry needs (www.innovatorslikeme.com)

LinkedIn

Twitter

An Innovation Portal…I Can Do That Myself

Innovation portals have taken an important place in the open innovation landscape. Expectations are great in portal performance but often, for purely budgetary reasons, these portals are launched and managed internally by corporates themselves, to discover that they generate a number of community management issues that they are not used to coping with. Prior to launching a corporate portal it is a good idea to ask a few specific questions on whether to do this internally or through experienced third party innovation providers. Using external resources can often avoid pitfalls and align the portal success rate to corporate expectations, objectives and ambitions. Here six questions are asked that can help you take the decision whether to launch a managed portal internally or externally.

PharmaX, the CEO’s Dilemma and Open Innovation – Part 3

In Parts 1 & 2, Gordon, newly appointed CEO of PharmaX, is confronted with a serious innovation gap in the next 5 years. His pipeline of projects is quality but high risk. From an arm’s length point of view, he sees that he has 3 options: business as usual, R&D budget cutting or rethink the way PharmaX assets are being used to redefine a new strategy. In Part 3 we will see how Gordon draws on his experience in customer needs driven innovation and managing his team, to carve out a daring innovation program.

PharmaX, the CEO’s Dilemma and Open Innovation – Part 2

In the first installment, Gordon the newly appointed CEO at Pharmax is confronted with an innovation gap of 5 years. Certainly, the potential of the portfolio is high, but the risks are even higher. With market pressure breathing down his neck, Gordon tries to make sense of the options that he has and make the right decisions.

PharmaX, the CEO’s Dilemma and Open Innovation – Part 1

We are on the executive floor of the imaginary pharmaceutical company PharmaX, it is Q3 and the top management is preparing for the annual innovation review. The year has been tough with revenue being hit by generic competition as their major products come off patent, but then it has been difficult for all the industry. This is the first article in a series of three. Parts 2 & 3 will be published in the next 2 weeks.

2019-10-15T15:14:48-07:00September 10th, 2013|Categories: Open Innovation, Strategies|Tags: , , , , , |

Open Innovation – An Integrated Tool in Siemens

“If Open Innovation is not seen as a long term capability building exercise then it will fail”. In this interview Thomas Lackner, Head of Open Innovation and Scouting at Siemens Corporate Technology, shares some of his experiences and how Siemens has evolved on the open innovation front. Thomas, who has been personally involved in many of Siemen’s innovation programs, also elaborates on some critical success factors that strongly influenced the outcome and quality of their programs.

A Hitchhiker’s Guide to Open Innovation in Corporate Venturing

Although plagued with mixed opinions that are influenced by mythology surrounding the investment industry, corporate venturing is finally resurfacing as an important component of the corporate innovation toolbox. As companies reassess the contribution that corporate venturing can make to their innovation objectives, it is critical that the fundamentals of corporate venturing are understood. This article addresses a number of important points to consider when applying corporate venturing in a global innovation strategy.